Physiomics (AIM:PYC) has secured multiple new and follow-on contracts totalling more than £345,000 with UK and international biotechnology and oncology-focused organisations, including a NASDAQ-listed clinical-stage biotechnology company.
The projects will deliver modelling and simulation, biometrics and data science to support Phase 1 and 2 clinical data analysis, first-in-human dose selection and ongoing clinical programme support, several are due to commence imminently and revenue is expected to flow through to the end of 2027, and Physiomics is a mathematical modelling, data science and biostatistics company supporting drug development and personalised medicine.
The awards, which span respected clinical-stage developers and leading cancer research groups, further broaden the company’s mix of new and repeat clients and, management says, deepen client relationships while diversifying the pipeline and strengthening the order book.
“These opportunities further strengthen our order book and improve revenue visibility across the business,” Dr Peter Sargent, CEO, said.
The company added that its broader pipeline remains strong and that it is progressing a number of additional opportunities it hopes to announce in due course.
